Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
13 drugs in development
By Therapeutic Area
top 3
R&D Momentum
93/100
Pipeline Velocity
70/100
Trial Completion Rate
69/100
Pipeline Concentration
39/100
Pipeline Freshness
61/100
Strategic Signals
Activity
Last 14 days
Mechanisms of Prediabetic States in Sleep Apnea
FITting Non-invasive Testing Into Lynch Syndrome Colorectal Cancer Surveillance: a Multi-center, Prospective Study
Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
Prediction and Prevention of Intracranial Hypertension and Tissue Hypoxia in Severe Traumatic Brain Injury
Health Impact of the "Recovery Legal Care" Medical-Legal Partnership
Recovery Legal Care Pilot (Cohort 1)
Impact of Tirzepatide on Lorlatinib-Associated Weight Gain and Metabolic Derangements in Patients With Non-Small Cell Lung Cancer (NSCLC)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)